What a difference a change in seasons makes.

This summer, Kirkland & Ellis found itself caught up in a conflict of interest controversy that simmered around its representation of Teva Pharmaceutical Industries over the Israeli generic drug giant’s $40 billion unsolicited bid for Mylan.